Statistical analysis showed that patients with cervical cancer had significantly higher levels of MMP-7 in stages I–II (median 491.60 ng/mL) and III–IV (566.90 ng/mL), MMP-10 in stages I–II (median 1586 ng/mL) and stages III–IV (2042 ng/mL), and MMP-26 in stages I–II (median 8.77 ng/mL) and stages III–IV (9.31 ng/mL) compared to patients with cervical dysplasia (CD) (median: MMP-7: 126.60 ng/mL; MMP-10: 484.30 ng/mL; MMP-26: 1.51 ng/mL). The gene discussed is MMP26; the disease is cervical carcinoma.